Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B
HBV
Tenofovir Disoproxil Fumarat - Phyllanthus Urinaria- Adenosma Glutinosum - Eclipta Prostrata - Ascorbic Acid is Effective in the Long-term Treatment of Chronic and Acute Hepatitis B.
1 other identifier
expanded_access
N/A
2 countries
2
Brief Summary
Phyllanthus Urinaria - Adenosma Glutinosum - Eclipta Prostrata - Ascorbic Acid combination plus Tenofovir in treatment of acute and chronic hepatitis B. Method the combination of drugs derived from natural and artificial medicaments. Has stronger effect on immune system, effective good against HBV replication. This is a substantial new insight into the pathogenesis of disease, with a clear path toward clinical application, or which would lead to a substantial advance and perfect in management or public health policy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 4, 2010
CompletedFirst Posted
Study publicly available on registry
September 10, 2010
CompletedDecember 15, 2025
December 1, 2025
September 4, 2010
December 7, 2025
Conditions
Keywords
Interventions
Drug: * Tenofovir * Phyllanthus Urinaria * Adenosma Glutinosum * Eclipta Prostrata * Ascorbic Acid
Eligibility Criteria
You may qualify if:
- Males and females ≥ 18 years of age with chronic and acute hepatitis B.
- Hepatitis B surface antigen (HBsAg)(+) for a minimum of 6 months prior to entry.
- Hepatitis B envelope antigen (HBeAg)(+) or (-) at baseline.
- Patients having treated or untreated
- Patients with compensated liver function (Child-Pugh score ≤ 6).
- Informed writted consent.
You may not qualify if:
- Any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol. or cytokine-based therapies with possible activity in hepatitis B disease within 6 months prior to study screening.
- Organ or bone marrow transplant recipients.
- Evidence of active liver disease to operate.
- Received immunoglobulins, interferon or other immune e to other causes (e.g., Wilson's disease, hemochromatosis, autoimmune hepatitis, hepatitis C, hepatitis D or HIV.)
- Patients taking parenteral (intravenous or intramuscular or subcutaneous) or oral steroids, immuno-suppressant therapies or chemotherapeutic agents within 2 months of study screening or expected to receive these agents during the course of the study.
- Clinically relevant alcohol or drug use or history of alcohol or drug use considered by the investigator to be sufficient to hinder compliance with treatment, follow up procedures or evaluation of adverse events.
- Hepatocellular carcinoma.
- Serious concurrent medical illness other than hepatitis B.
- History of hypersensitivity to nucleoside analogues.
- Women of childbearing potential not practising adequate contraception.
- Pregnancy or lactation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Saigon Biopharma LLC
Wilmington, Delaware, 19801-6601, United States
Saigon Biopharma Company Limited
Hồ Chí Minh, Ho Chi Minh City, 700000, Vietnam
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Nguyễn Thị Triệu, Dr.
Tran Minh Duc, Dr.